AI software developer iCAD has announced the appointment of Mark Koeniguer as its new chief commercial officer (CCO).
In the CCO role, Koeniguer will be responsible for commercial sales teams, partnerships, and operations for both North America and globally, the Nashua, NH-based iCAD said in a statement.
Koeniguer has previously served as CEO of ScreenPoint Medical; he has also held executive leadership roles at Riverain Technologies, Volpara Health, R2 Technology, Stereotaxis, and GE Healthcare.
iCAD is the developer of the AI-enabled mammography analysis ProFound Breast Health Suite for breast cancer detection, density assessment, and risk evaluation.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
